Clinical Trials

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03856216 2026-04-15

Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation

15 enrolled 11 charts

Burkitt Lymphoma, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03739814 2026-04-13

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

84 enrolled

Burkitt Lymphoma

NCT01679119 2026-04-07

INCA

129 enrolled 7 charts

Phase 2 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT05303792 2026-04-07

Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma

68 enrolled

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT04747912 2026-03-30

Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)

Phase 2 Suspended

25 enrolled

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06985485 2026-03-24

Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy

26 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05748171 2026-03-20

A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

100 enrolled

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02981628 2026-02-23

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

80 enrolled 1 FDA

Phase 2 Active not recruiting

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT03441061 2026-02-17

Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease

40 enrolled

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03913559 2026-02-12

Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia

5 enrolled

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06533748 2026-02-12

Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

128 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06387121 2025-12-17

Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL

53 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02877303 2025-11-06

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

80 enrolled

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT05645718 2025-10-07

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

Other hematologic neoplasm

27 enrolled

Leukemia

NCT06554626 2024-08-15

Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL

20 enrolled

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT06427330 2024-07-30

Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia

21 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01134575 2024-07-16

CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)

90 enrolled 10 charts

Burkitt Lymphoma, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03488225 2024-07-16

Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia

4 enrolled 11 charts

Burkitt Lymphoma

NCT03249870 2023-09-06

EWALL-INO

Phase 2 Unknown

130 enrolled

Philadelphia Chromosome, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03460522 2022-11-02

Inotuzumab Ozogamicin and Conventional Chemotherapy In Patients Aged 56 Years and Older With ALL

Phase 2 Unknown

65 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03610438 2022-01-04

ALL2418

Phase 2 Unknown

76 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03094611 2021-04-12

Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia

4 enrolled 12 charts

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00867087 2017-12-05

Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma

64 enrolled 15 charts

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00868608 2017-10-31

Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma

81 enrolled 24 charts

Lymphoma

NCT01363297 2017-04-13

Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia

72 enrolled 27 charts